Factors associated with mortality in Scottish patients receiving methadone in primary care: retrospective cohort study

C McCowan, B Kidd, T Fahey, C McCowan, B Kidd, T Fahey

Abstract

Objective: To assess predictors of mortality in a population of people prescribed methadone.

Design: Retrospective cohort study.

Setting: Geographically defined population in Tayside, Scotland.

Participants: 2378 people prescribed and dispensed liquid methadone between January 1993 and February 2004.

Main outcome measures: All cause mortality (primary outcome) and drug dependent cause specific mortality (secondary outcome) by means of Cox proportional hazards models during 12 years of follow-up.

Results: Overall, 181 (8%) people died. Overuse of methadone (adjusted hazard ratio 1.67, 95% confidence interval 1.05 to 2.67), history of psychiatric admission (2.47, 1.67 to 3.66), and increasing comorbidity measured as Charlson index >or=3 (1.20, 1.15 to 1.26) were all associated with an increase in all cause mortality. Longer duration of use (adjusted hazard ratio 0.95, 0.94 to 0.96), history of having urine tested (0.33, 0.22 to 0.49), and increasing time since last filled prescription were protective in relation to all cause mortality. Drug dependence was identified as the principal cause of death in 60 (33%) people. History of psychiatric admission was significantly associated with drug dependent death (adjusted hazard ratio 2.41, 1.25 to 4.64), as was history of prescription of benzodiazepines (4.35, 1.32 to 14.30).

Conclusions: Important elements of care in provision of methadone maintenance treatment are likely to influence, or be a marker for, a person's risk of death.

Conflict of interest statement

Competing interests: None declared.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4787452/bin/mccc635144.f1_default.jpg
Secular trends showing deaths and prescription items for methadone, Tayside 1993-2003. Two deaths and 2116 prescription items for methadone occurred in the period January to February 2004—data included in overall analysis but not presented in figure

References

    1. ISD Scotland. Drug misuse statistics Scotland 2002. Edinburgh: ISD Publications, 2003. (available at ).
    1. Department of Health. Statistics for the regional drug misuse databases. London: Department of Health, 2001.
    1. Krantz MJ, Mehler PS. Treating opioid dependence: growing implications for primary care. Arch Intern Med 2004;164:277-88.
    1. Gossop M, Stewart D, Treacy S, Marsden J. A prospective study of mortality among drug misusers during a 4-year period after seeking treatment. Addiction 2001;97:39-47.
    1. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2003;(2):CD002209.
    1. Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet 1999;353:221-6.
    1. Sporer KA. Strategies for preventing heroin overdose. BMJ 2003;326:442-4.
    1. Strang J, Sheridan J. Effect of national guidelines on prescription of methadone: analysis of NHS prescription data, England 1990-2001. BMJ 2003;327:321-2.
    1. Morgan O, Griffiths C, Hickman M. Association between availability of heroin and methadone and fatal poisoning in England and Wales 1993-2004. Int J Epidemiol 2006;35:1579-85.
    1. Weinrich M, Stuart M. Provision of methadone treatment in primary medical care practices: review of the Scottish experience and implications for US policy. JAMA 2003;283:1343-8.
    1. Advisory Council on the Misuse of Drugs. Reducing drug related deaths. London: Stationery Office, 2000.
    1. Squires T, Robertson R, Jay J, Robinson A, Bruce M. National Confidential Enquiry into Methadone Related Deaths (Scotland) 2000, 2000. .
    1. Hickman M, Madden P, Henry J, Baker A, Wallace C, Wakefield J, et al. Trends in drug overdose deaths in England and Wales 1993-98: methadone does not kill more people than heroin. Addiction 2003;98:419-25.
    1. Keen J. Managing drug misuse in general practice. BMJ 1999;318:1503-4.
    1. Royal College of General Practitioners. RCGP Substance Misuse Unit.
    1. Carstairs V, Morris R. Deprivation and health in Scotland. Health Bull 1990;48:162-75.
    1. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9.
    1. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 2004;57:1288-94.
    1. Department of Health, Scottish Office Department of Health, Welsh Office, Social Services Northern Ireland. Drug misuse and dependence—guidelines on clinical management. London: Stationery Office, 1999.
    1. Bradburn MJ, Clark TG, Love SB, Altman DG. Survival analysis part III: multivariate data analysis—choosing a model and assessing its adequacy and fit. Br J Cancer 2003;89:605-11.
    1. Zador D, Kidd B, Hutchinson S, Taylor A, Hickman M, Fahey T, et al. National investigation into drug related deaths in Scotland, 2003. Edinburgh: Scottish Executive, 2005.
    1. Oliver P, Keen J, Mathers N. Deaths from drugs of abuse in Sheffield 1997-1999: what are the implications for GPs prescribing to heroin addicts? Fam Pract 2002;19:93-4.
    1. Grimes DA, Schulz KF. Bias and causal associations in observational research. Lancet 2002;359:248-52.
    1. National Institute for Health and Clinical Excellence. Methadone and buprenorphine for the management of opioid dependence. London: NICE, 2007.
    1. Lawrinson P, Ali R, Buavirat A, Chiamwongpaet S, Dvoryak S, Habrat B, et al. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction 2008;103:1484-92.
    1. Gossop M. Maintenance treatments across countries. Addiction 2008;103:1493-4.
    1. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2003;(3):CD002208.
    1. Keen J, Oliver P, Rowse G, Mathers N. Does methadone maintenance treatment based on the new national guidelines work in a primary care setting? Br J Gen Pract 2003;53:461-7.
    1. National Prescribing Centre. The management of opioid dependence. MeReC Bulletin 2002;12(4):13-6.
    1. Hall W, Zador D. Challenge of reducing drug-related deaths. Lancet 2000;356:7-8.
    1. Bloor M, Gannon M, Hay G, Jackson G, Leyland AH, McKeganey N. Contribution of problem drug users’ deaths to excess mortality in Scotland: secondary analysis of cohort study. BMJ 2008;337:a478.
    1. Man LH, Best D, Gossop M, Stillwell G, Strang J. Relationship between prescribing and risk of opiate overdose among drug users in and out of maintenance treatment. Eur Addict Res 2004;10:35-40.
    1. Gossop M, Marsden J, Stewart D, Kidd T. The national treatment outcome research study (NTORS): 4-5 year follow-up results. Addiction 2003;98:291-303.
    1. Teesson M, Mills K, Ross J, Darke S, Williamson A, Havard A. The impact of treatment on 3 years’ outcome for heroin dependence: findings from the Australian treatment outcome study (ATOS). Addiction 2008;103:80-8.
    1. Chaudhry B, Wang J, Wu S, Maglione M, Mojica W, Roth E, et al. Systematic review: impact of health information technology on quality, efficiency, and costs of medical care. Ann Intern Med 2006;144:742-52.
    1. Stille CJ, Jerant A, Bell D, Meltzer D, Elmore JG. Coordinating care across diseases, settings, and clinicians: a key role for the generalist in practice. Ann Intern Med 2005;142:700-8.
    1. Law FD, Nutt DJ. Maintenance buprenorphine for opioid users. Lancet 2003;361:634-5.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj